Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
NEW YORK, March 03, 2016 -- Rosen Law Firm, a global investor rights law firm, announces that a class action lawsuit has been filed on behalf of purchasers of HeartWare International Inc. securities (NASDAQ:HTWR) from June 10, 2014 through January 11, 2016, all dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for HeartWare investors under the federal securities laws.
To join the HeartWare class action, go to the firm’s website at http://www.rosenlegal.com/cases-750.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants falsely assured investors that HeartWare had adequately addressed numerous manufacturing and other regulatory failures at HeartWare’s sole manufacturing facility, and that the failures, which had been identified by the U.S. Food and Drug Administration (FDA) in a Warning Letter, posed no risk to the clinical trials or timely approval of MVAD, a pump that HeartWare is presently developing. When the true details concerning HeartWare’s failure to remediate the regulatory problems identified by the FDA and its impact on MVAD entered the market, HeartWare’s share price declined, causing investors damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://www.rosenlegal.com/cases-750.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
